Pharmacia

Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

Retrieved on: 
Thursday, December 15, 2022
Research, Venture Capital, Professional Services, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Therapy, Lymphoma, Medivation, University, JD, Rb, Cell cycle, IND, Doctor of Philosophy, Royal London Hospital, Drug discovery, Cancer, Circle, Research, Imetelstat, Genentech, NYSE, Geron Corporation, Cell, MRNA, Pharmacia, Pharma, Squamous cell carcinoma, St. Bartholomew's, Hoffmann-La Roche, PFE, Leukemia, Cyclin A, Hematological Cancer Research Investment and Education Act, Pharmaceutical industry, Pfizer

Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors.

Key Points: 
  • Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors.
  • Dr. Kelsey has had key roles in the development of many oncology therapeutics including Sutent, Perjeta, Kadcycla, Erivedge and imetelstat.
  • Im delighted to welcome Steve to our Board, said David J. Earp, JD, PhD, Circles president and CEO.
  • Im excited to join Circles Board and to help the company bring its promising therapies to cancer patients.

NeoDynamics appoints Matthew Colpoys, to lead US operations

Retrieved on: 
Thursday, December 1, 2022
Diagnosis, John Colpoys, Insming, Therapy, Strategic planning, Cancer, Genentech, Pharmaceutical industry, Elan, Pfizer, Pharmacia

Colpoys will remain on the board and will report to CEO Anna Eriksrud.

Key Points: 
  • Colpoys will remain on the board and will report to CEO Anna Eriksrud.
  • "Matt is an experienced executive with an extensive background in new product launches, commercialization and corporate finance.
  • He has also guided international companies in US launch efforts in the past - a perfect fit for NeoDynamics as we move quickly to introduce our innovative pulse biopsy system NeoNavia to the US market," said Anna Eriksrud CEO of NeoDynamics.
  • Most recently he founded and led Tactiva Therapeutics, Inc., an Immuno-Oncology start up, through their $35M Series A fund raise.

Baron & Budd Obtains $537.5 Million Class Settlement for 2,442 Public Entities in Monsanto Water Contamination Lawsuit

Retrieved on: 
Monday, November 21, 2022
Class Action Lawsuit, Professional Services, Legal, Baron & Budd, P.C., Polychlorinated biphenyl, City, Bayer, Environment, Pharmacia, PCB, Mesothelioma, Government, Animal, Motor vehicle, Port of Portland (Oregon), Monsanto, Total maximum daily load, Port, Human, Tissue, Atmosphere, Asbestos, Soil, County, P.C, Health, Water, Pharmaceutical industry, Insurance, Landfill

announced final approval of a nationwide class action settlement with Monsanto Company, Pharmacia, LLC, Solutia, Inc., and Bayer arising from environmental contamination caused by PCBs.

Key Points: 
  • announced final approval of a nationwide class action settlement with Monsanto Company, Pharmacia, LLC, Solutia, Inc., and Bayer arising from environmental contamination caused by PCBs.
  • The $537.5 million settlement provides cash payments to a class of 2,442 government entities across the country.
  • This settlement will provide funds directly to public entities burdened with reducing PCBs from stormwater and sediment, said Co-Lead Class Counsel and Baron & Budd Shareholder Scott Summy .
  • PCBs are one of the largest water contaminants in the world, said Co-Lead Class Counsel and Baron & Budd Shareholder John Fiske.

NeoDynamics hires National Sales Director for the launch of its NeoNavia® Biopsy System

Retrieved on: 
Tuesday, November 8, 2022
Nasdaq, Genentech, Diagnosis, Infection, Cancer, Pharmacia, Carney, CEO, Patient, Technology, Endocrinology, Pharmaceutical industry, Medical imaging

He will lead commercial strategy and execution, including field sales and managed markets for the company.

Key Points: 
  • He will lead commercial strategy and execution, including field sales and managed markets for the company.
  • Mr. Carney has more than 20 years of experience including Genentech and Pharmacia, leading teams and product launches in oncology, infectious diseases, endocrinology, and medical devices.
  • He has most recently served as Sr. Director, Market Access for Syneos Health where he led cross-functional teams launching novel therapies in Oncology and Women's Health.
  • "Brendan brings to NeoDynamics a history of significant and successful experience running commercial teams.

Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs

Retrieved on: 
Monday, October 24, 2022
CFO, LAVA, Deloitte, NASDAQ, Depression, Publication, Corporation, Benitec Biopharma, University, Medicine, University of Lynchburg, CEO, Phrase, Physician assistant, LLP, Professional practice of behavior analysis, Therapy, Toronto Stock Exchange, Reunion, Neuroscience, Professional Psychology: Research and Practice, Cancer, Private Securities Litigation Reform Act, Pharmacia, Yale school, Distinguished Fellow of the British Computer Society, Medical Affairs Bureau, Company, Industry, Certified Public Accountant, Yale School of Medicine, American Academy, GLOBE, EDGAR, Assistant, Risk, Time, TSX, Field trip, Mental health, Aviva, Board, University of Hartford, Salix Pharmaceuticals, Inflammation, AstraZeneca, Hartford, Connecticut, Patient, Acquisition, Financial management, Research, SEDAR, Pharmaceutical industry

TORONTO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the Company), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it has appointed Edward Smith as the Companys Chief Financial Officer and Aviva Asnis-Alibozek as Vice President, Medical Affairs, effective immediately.

Key Points: 
  • TORONTO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the Company), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it has appointed Edward Smith as the Companys Chief Financial Officer and Aviva Asnis-Alibozek as Vice President, Medical Affairs, effective immediately.
  • Dr. Asnis-Alibozek earned her Doctor of Medical Science degree in the advanced professional practice of administrative medicine from the University of Lynchburg.
  • Edward Smith succeeds Donna Wong who has resigned as Chief Financial Officer.
  • To be added to the Reunion Neuroscience email list, please email [email protected] with REUN in the subject line.

RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires

Retrieved on: 
Wednesday, September 28, 2022
Jazz Pharmaceuticals, UNC Gillings School of Global Public Health, Inflammation, Onyx Pharmaceuticals, CCR4, Alopecia areata, Cell biology, Arena Pharmaceuticals, Company, Senior, Growth, Hematology, NDA, Rutgers University, Therapy, Atopic dermatitis, Â, Patient, Regulatory affairs, Cancer, University of North Carolina at Charlotte, Amgen, AstraZeneca, Commercial, RAPT, University of California, San Diego, University of Cambridge, Quality assurance, Denosumab, SAN, Biotechnology, Bavarian Nordic, GLOBE, Marketing, Pharmacia, Procter & Gamble, Genentech, Pleasure, Asthma, University, Pfizer, Chapel Hill, Acalabrutinib, Pharmaceutical industry, Biochemistry, Dermatology

It is a pleasure to welcome both Jennifer and Adnan to the RAPT leadership team at this exciting time of growth for the Company, said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics.

Key Points: 
  • It is a pleasure to welcome both Jennifer and Adnan to the RAPT leadership team at this exciting time of growth for the Company, said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics.
  • Prior to Kronos Bio, she was Head of Global Regulatory Science at Acerta Pharma, a member of the AstraZeneca Group.
  • RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology.
  • RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively.

Nicox Provides First Half 2022 Business Update and Financial Results

Retrieved on: 
Friday, September 16, 2022
Mont Blanc, Kepler, Glaucoma, Clinical trial, Patient, Fluticasone, University of California, San Diego Performance-Based Skills Assessment, Research, Allergic conjunctivitis, COVID-19, Johannes Kepler, Company, KREO (FM), Â, COX, Retina, Nitric oxide, Duane syndrome, Latanoprost, Audit committee, Board, Intraocular pressure, Dolomites, 470, Ocular hypertension, Vichy, IOP, NCX, LLC, Bausch & Lomb, Therapy, Program, Pharmacia, University, NO, Euronext Paris, Compartment, Pharmaceutical industry, Fine chemical, Ophthalmology

Topline results from first pivotal Phase 3 glaucoma clinical trial on NCX 470, Mont Blanc, due in November 2022

Key Points: 
  • Topline results from first pivotal Phase 3 glaucoma clinical trial on NCX 470, Mont Blanc, due in November 2022
    Net revenue 1.4 million for H1 2022; cash of 31.6 million on June 30, 2022
    Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided business and financial results for Nicox SA and its subsidiaries (the Nicox Group) for the first half of 2022.
  • I am delighted to have joined Nicox at such an important time in the companys history.
  • Operating expenses for the first half of 2022 were 12.7 million compared to 13.4 million for the first half of 2021.
  • Nicox disavows any obligation to correct or to update the information contained in analyst reports.

STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer

Retrieved on: 
Wednesday, September 7, 2022
MedImmune, AstraZeneca, Pharmacia, Rensselaer Polytechnic Institute, Enzyme, Inflammation, University, Human, CEO, RNA, Cancer, IP Group, McMahon, CNS, Sunitinib, Global Partnership for Education, Therapy, Genetics, NASDAQ, BS, Doctor of Philosophy, Tufts University School of Medicine, FTI, Massachusetts Institute of Technology, Board, IPO, SUGEN, RME, Senior, STORM, METTL3, Biology, Company, Yale University, FDA, Biotechnology, Merck, Merck Group, Degenerative disease, Biochemistry, Drug discovery, Growth, Trial of the century, Patient, Pharmaceutical industry, Vaccine, IND, Pfizer

CAMBRIDGE, England, Sept. 7, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director.

Key Points: 
  • CAMBRIDGE, England, Sept. 7, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director.
  • Dr. Jerry McMahon added:"STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME.
  • Dr. McMahon was President and CEO of NASDAQ listed Harpoon Therapeutics, building the Company from early stage through to IPO, follow-on financings, and development collaborations.
  • STORM Therapeutics (STORM) is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer

Retrieved on: 
Wednesday, September 7, 2022
MedImmune, AstraZeneca, Pharmacia, Rensselaer Polytechnic Institute, Enzyme, Inflammation, University, Human, CEO, RNA, Cancer, IP Group, McMahon, CNS, Sunitinib, Global Partnership for Education, Therapy, Genetics, NASDAQ, BS, Doctor of Philosophy, Tufts University School of Medicine, FTI, Massachusetts Institute of Technology, Board, IPO, SUGEN, RME, Senior, STORM, METTL3, Biology, Company, Yale University, FDA, Biotechnology, Merck, Merck Group, Degenerative disease, Biochemistry, Drug discovery, Growth, Trial of the century, Patient, Pharmaceutical industry, Vaccine, IND, Pfizer

CAMBRIDGE, England, Sept. 7, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director.

Key Points: 
  • CAMBRIDGE, England, Sept. 7, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director.
  • Dr. Jerry McMahon added:"STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME.
  • Dr. McMahon was President and CEO of NASDAQ listed Harpoon Therapeutics, building the Company from early stage through to IPO, follow-on financings, and development collaborations.
  • STORM Therapeutics (STORM) is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

Retrieved on: 
Thursday, September 1, 2022
Pharmacia, Neoplasm, COVID-19, CEO, Technology, Cancer prevention, Cancer, XV, Research, Squamous cell carcinoma, Alpha Sigma Tau, Therapy, Pfizer, Private Securities Litigation Reform Act, Xi, Risk, OSI, Hope, SEC, U.S. Securities and Exchange Commission, McGill University, 100,000, GLOBE, Nasdaq, Erlotinib, Chief commercial officer, Annual report, Marketing, OSI Pharmaceuticals, Vii, Alpha Tau Delta, Bristol Myers Squibb, Patient, Pharmaceutical industry, Tel Aviv University, Alpha

JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Companys Board of Directors in order to assume the full-time position of Alpha Taus Chief Commercial Officer.

Key Points: 
  • JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Companys Board of Directors in order to assume the full-time position of Alpha Taus Chief Commercial Officer.
  • Before that, he served as Chief Commercial Officer of Novocure, and led the construction of the global commercial platform and infrastructure for the launch of Novocures Optune product.
  • Prior to OSI, Mr. Melnyk was executive director of oncology at Pfizer and Pharmacia and a director of oncology at Bristol-Myers Squibb.
  • We are thrilled to bring Peter in to lead our commercialization efforts, said Alpha Tau CEO Uzi Sofer.